Pan-cancer characterization of ncRNA synergistic competition uncovers potential carcinogenic biomarkers

Junpeng Zhang1, Lin Liu2, Xuemei Wei1

  • 1School of Engineering, Dali University, Dali, Yunnan, People's Republic of China.

PubMed

Insights

This study introduces SCOM, a framework for identifying synergistic competition among non-coding RNAs (ncRNAs) in 31 cancers. It reveals shared ncRNAs in tumors, linked to drug resistance and immune regulation, aiding biomarker discovery.

Area of Science:

  • Genomics
  • Molecular Biology
  • Cancer Research

Background:

  • Non-coding RNAs (ncRNAs) are key regulators of gene expression.
  • ncRNAs play critical roles in cancer physiology and development.
  • Understanding competing endogenous RNA (ceRNA) networks offers insights into ncRNA-driven tumorigenesis.

Purpose of the Study:

  • To develop a framework (SCOM) for identifying synergistic ncRNA competition.
  • To systematically map the landscape of ncRNA synergistic competition across 31 malignant tumors.
  • To explore the functional implications of ncRNA synergistic competition in cancer.

Main Methods:

  • Development of the SCOM computational framework.
  • Systematic analysis of ncRNA synergistic competition across a large cohort of cancer types.
  • Investigation of associations between synergistic competition ncRNAs and clinical/biological features.

Main Results:

  • Malignant tumors exhibit shared hub ncRNAs in synergistic competition networks.
  • ncRNAs involved in synergistic competition are associated with drug resistance.
  • These ncRNAs contribute to distinguishing cancer subtypes and immune regulation.

Conclusions:

  • The SCOM framework facilitates the identification of ncRNA synergistic competition.
  • SCOM aids in uncovering potential diagnostic and prognostic biomarkers for malignant tumors.
  • The SCOMdb database provides a valuable resource for ncRNA research in cancer.

Related Concept Videos

Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.3K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.0K